NCT05455619
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05455619
Title Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/ Her2- Breast Cancer (Amelia-1)
Acronym Amelia-1
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors SynDevRx, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Loma Linda University Cancer Center RECRUITING Loma Linda California 92354 United States Details
Hoag Memorial Hospital Presbyterian RECRUITING Newport California 92663 United States Details
SHARP Healthcare RECRUITING San Diego California 92123 United States Details
Miami Cancer Institute at Baptist Health RECRUITING Miami Florida 33176 United States Details
Hope and Healing Cancer Services RECRUITING Hinsdale Illinois 60521 United States Details
Trinity Health RECRUITING Ypsilanti Michigan 48197 United States Details
Cleveland Clinic RECRUITING Cleveland Ohio 44195 United States Details
Penn State Milton S Hershey Medical Center RECRUITING Hershey Pennsylvania 17033 United States Details
Vanderbilt University Medical Center RECRUITING Nashville Tennessee 37232 United States Details
Doctors Hospital of Laredo RECRUITING Laredo Texas 78045 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field